Hosted by HealthpointCapital
Hosted by HealthpointCapital
GID BIO is a late-clinical-stage medical device company pioneering a point-of-care autologous cell therapy platform for treating chronic degenerative diseases, starting with knee osteoarthritis (OA). This condition affects over 30 million Americans. By harnessing each patient’s own stromal vascular cells- not stem cells- GID BIo provides a same day outpatient procedure that has shown in its phase 3 FDA IDE trial, statistical significance versus placebo, to reduce pain by 73% and improve function by 115% at one year, with long term durability 2.5 -4 years post a single injection. GID’s patented disposable device isolates and concentrates over 25+ million stromal cells from a small sample of a patient’s adipose tissue (fat). The company has filed its PMA application with commercialization planned for Q3 2027 with strong reimbursement.
